Abstract
The authors set out to investigate whether NAP-related peptides interact with tubulin at a NAP binding site. Previous studies have shown that the neuroprotective peptide NAP binds to tubulin. As NAP (NAPVSIPQ) shares structural similarities with ADNF-9 (SALLRSIPA), and the all-d-enantiomers, d-NAP and d-SAL, it was hypothesized that all of these peptides compete with NAP-tubulin binding. Using NAP affinity column and extracts from newborn rat brain (cerebral cortex), we now show that the above-mentioned peptides compete with NAP binding to tubulin. The identification of tubulin as a target binding site for NAP-related peptides explains, in part, the broad neuroprotective activity offered by these potent peptides.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bassan M., Zamostiano R., Davidson A., et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72, 1283–1293.
Blondel O., Collin C. McCarran W. J., et al. (2000) A gliaderived signal regulating neuronal differentiation. J. Neurosci. 20, 8012–8020.
Brenneman D. E. and Eiden L. E. (1986) Vasoactive intestinal peptide and electrical activity influence neuronal survival, Proc. Natl. Acad. Sci. U. S. A. 83, 1159–1162.
Brenneman D. E. and Gozes I. (1996) Afemtomolar-acting neuroprotective peptide. J. Clin. Invest., 97, 2299–2307.
Brenneman D. E., Hauser J., Neale E., et al. (1998). Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J. Pharmacol. Exp. Ther. 185, 619–627.
Brenneman D. E., Spong C. Y., Hauser J. M., et al. (2004) Protective peptides that are orally active and mechanistically nonchiral, J. Pharmacol. Exp. Ther. 309, 1190–1197.
Divinski I., Mittelman, L., and Gozes, I. (2004). A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 279, 28, 531–538.
Furman S., Steingart R. A., Mandel S., Hauser J. M., Brenneman D. E., and Gozes I. (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biology, 1, 193–199.
Gozes I. and Littauer U. Z. (1978). Tubulin microheterogeneity increases with rat brain maturation. Nature 276, 411–413.
Gozes I. and Sweadner K. J. (1981). Multiple tubulin forms are expressed by a single neurone. Nature, 294, 477–480.
Gozes I. and Barnstable, C. J. (1982). Monoclonal antibodies that recognize discrete forms of tubulin. Proc. Natl. Acad. Sci. U. S. A., 79, 2579–2583.
Gozes I. and Littauer U. Z. (1982). Microtubule protein: tubulin. Scand. J. Immunol. 9 (Suppl.), 299–316.
Gozes I., Bardea A., Reshef A., et al. (1996) Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci U. S. A., 93, 427–432.
Gozes I. and Brenneman D. E. (1996) Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J. Mol. Neurosci. 7, 235–44.
Gozes I., Bachar M., Bardea A., et al. (1997) Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. J. Neurobiol. 33, 329–342.
Gozes I. and Brenneman D. E. (2000) A new concept in the pharmacology of neuroprotection. J. Mol. Neurosci. 14, 61–68.
Gozes I., Steingart R. A., and Spier A. D. (2004) NAP mechanisms of neuroprotection. J. Mol. Neurosci. 24, 67–72.
Gozes I. and Divinski I. (2004). The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J. Alzheimers Dis. 6, S37-S41.
Gozes I., Zaltzman R., Hauser J., Brenneman D. E., Shohami E., and Hill J. M. (2005) The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr. Alzheimer Res. 2, 149–153.
Glazner G. W., Boland A., Dresse A. E., Brenneman D. E., Gozes I., and Mattson M. P. (1999) Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J. Neurochem. 73, 2341–2347.
Glazner G. W., Gressens P., Lee S. J., et al. (1999) Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development. Anat. Embryol. (Berl). 200, 65–71.
Glazner G. W. and Mattson M. P. (2000) Differential effects of BDNF, ADNF9, and TNFalpha on levels of NMDA receptor subunits, calcium homeostasis, and neuronal vulnerability to excitotoxicity. Exp. Neurol., 161, 442–452.
Gressens P., Hill J. M., Gozes I., Fridkin M., and Brenneman D. E. (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362, 155–158.
Guo Q., Sebastian L., Sopher B. L., et al. (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl. Acad. Sci. U.S.A. 96, 4125–4130.
Guo Z. H. and Mattson M. P. (2000) Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb. Cortex 10, 50–57.
Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D. E., and Gozes I. (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854, 257–262.
Pinhasov A., Mandel S., Torchinsky A., et al. (2003). Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 144, 83–90.
Roy S., Zhang B., Lee V. M., and Trojanowski J. Q. (2005) Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. (Berl). 109, 5–13.
Spong C. Y., Abebe D. T., Gozes I., Brenneman D. E., and Hill J. M. (2001) Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J. Pharmacol. Exp. Ther. 297, 774–779.
Steingart R. A., Solomon B., Brenneman D. E., Fridkin M., and Gozes I. (2000) VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J. Mol. Neurosci. 15, 137–145.
White D. M., Walker S., Brenneman D. E., and Gozes I. (2000) CREB contributes to the increased neurite outgrowth of sensory neurons induced by vasoactive intestinal polypeptide and activity-dependent neurotrophic factor. Brain Res. 868, 31–38.
Wilkemeyer M. F., Chen S. Y., Menkari C. E., Brenneman D. E., Sulik K. K., and Charness M. E. (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc. Natl. Acad. Sci. U.S.A., 100, 8543–8548.
Zamostiano R., Pinhasov A., Gelberg E., et al. (2001). Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem., 276, 708–714.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holtser-Cochav, M., Divinski, I. & Gozes, I. Tubulin is the target binding site for NAP-related peptides. J Mol Neurosci 28, 303–307 (2006). https://doi.org/10.1385/JMN:28:3:303
Received:
Issue Date:
DOI: https://doi.org/10.1385/JMN:28:3:303